EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY

Masaomi Nangaku, William G Herrington, Shinya Goto, Shoichi Maruyama, Naoki Kashihara, Kohjiro Ueki, Jun Wada, Hirotaka Watada, Eitaro Nakashima, Ryonfa Lee, Dan Massey, Kaitlin J Mayne und 4 weitere

Clinical and Experimental Nephrology · 2024-06 · 28 (6) · 588-595

DOI: 10.1007/s10157-024-02489-4 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Experimental Nephrology, online erschienen am 20.04.2024. Verfasst von Masaomi Nangaku und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Endocrinology, The University of Tokyo School of Medicine, Tokyo, 113-8655, Japan. mnangaku@m.u-tokyo.ac.jp. Hauptthemen laut MEDLINE: Glucosides, Renal Insufficiency, Chronic, Benzhydryl Compounds, Glomerular Filtration Rate. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Boehringer Ingelheim, Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

EMPA–KIDNEY assessed the effects of empagliflozin 10 mg once daily vs. placebo in 6609 patients with chronic kidney disease (CKD) at risk of progression, including 612 participants from Japan.

Methods

Eligibility required an estimated glomerular filtration rate (eGFR) of ≥ 20 < 45; or ≥ 45 < 90 ml/min/1.73m 2 with a urinary albumin-to-creatinine ratio (uACR) of ≥ 200 mg/g. The primary outcome was a composite of kidney disease progression (end-stage kidney disease, a sustained eGFR decline to < 10 ml/min/1.73m 2 or ≥ 40% from randomization, or renal death) or cardiovascular death. In post-hoc analyses, we explored the effects of empagliflozin in participants from Japan vs. non-Japan regions, including additional models assessing whether differences in treatment effects between these regions could result from differences in baseline characteristics.

Results

Japanese participants had higher levels of albuminuria and eGFR than those from non-Japan regions. During a median of 2.0 year follow-up, a primary outcome occurred in 432 patients (13.1%) in the empagliflozin group and in 558 patients (16.9%) in the placebo group (hazard ratio [HR], 0.72, 95% confidence interval [95%CI] 0.64–0.82; P < 0.0001). Among the participants from non-Japan regions, there were 399 vs. 494 primary outcomes (0.75, 0.66–0.86), and 33 vs. 64 (0.49, 0.32–0.75; heterogeneity p = 0.06) in Japan. Results were similar when models explicitly considered treatment interactions with diabetes status, categories of eGFR/uACR, and recruitment in Japan (heterogeneity p = 0.08). Safety outcomes were broadly comparable between the two groups, and by Japanese status.

Conclusions

Empagliflozin safely reduced the risk of “kidney disease progression or cardiovascular death” in patients with CKD, with consistent effects in participants from Japan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesRenal Insufficiency, ChronicBenzhydryl CompoundsGlomerular Filtration RateSodium-Glucose Transporter 2 InhibitorsDisease ProgressionAlbuminuriaHumansMaleFemaleMiddle AgedJapanAgedTreatment OutcomeKidneyDouble-Blind MethodKidney Failure, ChronicCardiovascular Diseases

Stichwörter der Autor:innen

Cardiovascular diseaseKidney functionRandomised trialSodium–glucose co-transporter-2 inhibitor

Substanzen

empagliflozinGlucosidesBenzhydryl CompoundsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Division of Nephrology and Endocrinology, The University of Tokyo School of Medicine, Tokyo, 113-8655, Japan. mnangaku@m.u-tokyo.ac.jp.
  • Medical Research Council Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Tokai University School of Medicine, Isehara, Japan.
  • Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Kawasaki Medical School, Kurashiki, Japan.
  • Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.

Förderung

  • Medical Research Council
  • Boehringer Ingelheim
  • Eli Lilly and Company
  • Health Data Research UK
  • National Institute for Health and Care Research
  • The University of Tokyo

Zitieren

APA

Nangaku, M., Herrington, W. G., Goto, S., Maruyama, S., Kashihara, N., Ueki, K., Wada, J., Watada, H., Nakashima, E., Lee, R., Massey, D., Mayne, K. J., Tomita, A., Haynes, R., Hauske, S. J., & Kadowaki, T. (2024). Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY. Clinical and Experimental Nephrology, 28(6), 588-595. https://doi.org/10.1007/s10157-024-02489-4

Vancouver

Nangaku M, Herrington WG, Goto S, Maruyama S, Kashihara N, Ueki K, et al. Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY. Clinical and Experimental Nephrology. 2024;28(6):588-595. doi:10.1007/s10157-024-02489-4

BibTeX
@article{Nangaku2024,
  author = {Nangaku, Masaomi and Herrington, William G and Goto, Shinya and Maruyama, Shoichi and Kashihara, Naoki and Ueki, Kohjiro and Wada, Jun and Watada, Hirotaka and Nakashima, Eitaro and Lee, Ryonfa and Massey, Dan and Mayne, Kaitlin J and Tomita, Aiko and Haynes, Richard and Hauske, Sibylle J and Kadowaki, Takashi},
  title = {Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY},
  journal = {Clinical and Experimental Nephrology},
  year = {2024},
  volume = {28},
  number = {6},
  pages = {588--595},
  doi = {10.1007/s10157-024-02489-4}
}
Kostenlos starten →